By proceeding, you agree to our Terms of Use and Privacy Policy.
Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins.
12-14 July 2022
From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models – Deepen Our Understanding of Tumor Biology, Resistance Mechanisms & Dosing Strategy Following the success of KRAS, HER2, BCMA, drug developers ha
Event Ended
USA
Paid
Boston
24-26 January 2023
With 2023 on track to see further growth in the immuno-oncology field, the availability of tools that offers drug developers & researchers advantages that weren’t available to them even a few years ago is increasing rapidly.
San Francisco
12-13 July 2023
The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encourage